Carvykti® (Ciltacabtagene Autoleucel) Approved by the European Commission for Second-Line Treatment of Patients With Relapsed and Refractory Multiple Myeloma
Carvykti®(Ciltacabtagene Autoleucel)获欧盟委员会批准,用于复发和难治性多发性骨髓瘤患者的二线治疗
Carvykti® (Ciltacabtagene Autoleucel) Approved by the European Commission for Second-Line Treatment of Patients With Relapsed and Refractory Multiple Myeloma
Carvykti®(Ciltacabtagene Autoleucel)获欧盟委员会批准,用于复发和难治性多发性骨髓瘤患者的二线治疗
使用浏览器的分享功能,分享给你的好友吧